Table 3.
Self-reported Sleep Outcomes from Laboratory and Home Nights†
| Sleep Latency (minutes) | WASO (minutes) | Sleep Efficiency (%) | Sleep Quality (1-9) | |
|---|---|---|---|---|
| Sleep Laboratory Nights‡ | ||||
| Baseline | 14.3 (8.5) | 17.5 (16.4) | 93.4 (5.2) | 6.1 (1.6) |
| Single Night | ||||
| Valerian | 14.8 (11.5) | 28.3 (37.5) | 93.6 (7.5) | 6.0 (1.6) |
| Placebo | 14.8 (9.9) | 28.3 (30.5) | 90.6 (9.5) | 6.2 (1.3) |
| Two-weeks | ||||
| Valerian | 24.7 (23.3) | 32.0 (32.0) | 88.9 (8.7) | 5.9 (1.8) |
| Placebo | 22.7 (22.0) | 36.0 (45.6) | 87.9 (12.7) | 6.4 (1.4) |
| Home Nights‡ | ||||
| Baseline | 30.7 (24.3) | 52.0 (41.3) | 83.8 (10.3) | 5.9 (1.3) |
| First Week | ||||
| Valerian | 23.3 (16.2) | 47.2 (28.5) | 85.9 (8.1) | 5.9 (1.0) |
| Placebo | 21.3 (12.6) | 48.3 (32.3) | 86.4 (7.2) | 6.2 (0.9) |
| Second Week | ||||
| Valerian | 20.8 (21.8) | 43.4 (30.1) | 87.8 (8.6) | 6.5(0.9) |
| Placebo | 18.6 (11.8) | 55.9 (48.6) | 85.3 (11.0) | 6.4 (0.9) |
Data are presented as mean (standard deviation). Wake after sleep onset = WASO
†
Wilcoxon signed-ranks, two-sided, were used to evaluate the primary outcome valerian versus placebo, all p > .05
‡
Sleep laboratory nights: baseline = mean of Night 1 and Night 2, single night = Night 3/31 only, two-week dose = mean of the last two dosing nights (Nights 15 & 16/Nights 43 & 44). Home nights: baseline = mean of last five screening nights, first week = mean of the first five home nights (Nights 4-8/Nights 32-36), and second week = mean of the last five home nights (Nights 10-14/Nights 38-42).